AU2017380282B2 - Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors - Google Patents
Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors Download PDFInfo
- Publication number
- AU2017380282B2 AU2017380282B2 AU2017380282A AU2017380282A AU2017380282B2 AU 2017380282 B2 AU2017380282 B2 AU 2017380282B2 AU 2017380282 A AU2017380282 A AU 2017380282A AU 2017380282 A AU2017380282 A AU 2017380282A AU 2017380282 B2 AU2017380282 B2 AU 2017380282B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- pyran
- compound
- methyl
- isoindolin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021203497A AU2021203497B2 (en) | 2016-12-22 | 2021-05-28 | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20166024 | 2016-12-22 | ||
| FI20166024 | 2016-12-22 | ||
| PCT/FI2017/050926 WO2018115591A1 (en) | 2016-12-22 | 2017-12-21 | Pyran dervatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021203497A Division AU2021203497B2 (en) | 2016-12-22 | 2021-05-28 | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017380282A1 AU2017380282A1 (en) | 2019-08-01 |
| AU2017380282B2 true AU2017380282B2 (en) | 2021-06-24 |
Family
ID=61005837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017380282A Active AU2017380282B2 (en) | 2016-12-22 | 2017-12-21 | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
| AU2021203497A Active AU2021203497B2 (en) | 2016-12-22 | 2021-05-28 | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021203497A Active AU2021203497B2 (en) | 2016-12-22 | 2021-05-28 | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10717726B2 (enExample) |
| EP (2) | EP3868756A1 (enExample) |
| JP (2) | JP7025432B2 (enExample) |
| KR (3) | KR20250097993A (enExample) |
| CN (2) | CN116162084B (enExample) |
| AR (1) | AR110412A1 (enExample) |
| AU (2) | AU2017380282B2 (enExample) |
| CA (1) | CA3047370A1 (enExample) |
| CL (1) | CL2019001728A1 (enExample) |
| CO (1) | CO2019007321A2 (enExample) |
| CY (1) | CY1124461T1 (enExample) |
| DK (1) | DK3558981T3 (enExample) |
| EA (1) | EA039309B1 (enExample) |
| ES (1) | ES2880151T3 (enExample) |
| HR (1) | HRP20211255T1 (enExample) |
| HU (1) | HUE056540T2 (enExample) |
| IL (2) | IL267484B (enExample) |
| LT (1) | LT3558981T (enExample) |
| MA (2) | MA47102B1 (enExample) |
| MX (1) | MX388538B (enExample) |
| NZ (1) | NZ755395A (enExample) |
| PE (1) | PE20191137A1 (enExample) |
| PH (1) | PH12019550111A1 (enExample) |
| PL (1) | PL3558981T3 (enExample) |
| PT (1) | PT3558981T (enExample) |
| RS (1) | RS62198B1 (enExample) |
| SI (1) | SI3558981T1 (enExample) |
| TN (1) | TN2019000189A1 (enExample) |
| TW (2) | TWI796205B (enExample) |
| UA (1) | UA124640C2 (enExample) |
| WO (1) | WO2018115591A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
| CN115551831A (zh) | 2020-05-14 | 2022-12-30 | 奥赖恩公司 | Cyp11a1抑制剂 |
| WO2022117920A1 (en) | 2020-12-01 | 2022-06-09 | Orion Corporation | 2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancer |
| AU2022228710A1 (en) * | 2021-03-01 | 2023-09-07 | Orion Corporation | Process for the preparation of a cyp11a1 inhibitor and intermediates thereof |
| US20240158378A1 (en) | 2021-03-01 | 2024-05-16 | Orion Corporation | Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor |
| AR124985A1 (es) | 2021-03-01 | 2023-05-24 | Orion Corp | Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona |
| US20240336603A1 (en) | 2021-06-23 | 2024-10-10 | Orion Corporation | Process for the preparation of a cyp11a1 inhibitor and intermediates thereof |
| CA3232600A1 (en) * | 2021-09-28 | 2023-04-06 | Tarja IKONEN | Cyp11a1 inhibitor for use in the treatment of prostate cancer |
| WO2023073285A1 (en) | 2021-10-28 | 2023-05-04 | Orion Corporation | Salt forms of a 4h-pyran-4-one structured cyp11 at inhibitor |
| US20250011285A1 (en) | 2021-11-10 | 2025-01-09 | Orion Corporation | Cyp11a1 inhibitors |
| JP2025502308A (ja) | 2022-01-20 | 2025-01-24 | オリオン・コーポレーション | Ｃｙｐ１１ａ１阻害剤の医薬組成物 |
| CN118307519A (zh) | 2023-01-06 | 2024-07-09 | 上海闻耐医药科技有限公司 | 一类cyp11a1抑制剂化合物及其制备方法和用途 |
| KR20240126916A (ko) | 2023-02-14 | 2024-08-22 | 경북대학교 산학협력단 | Asm 단백질 또는 이의 단편을 포함하는 퇴행성 신경질환 또는 우울증 예방 또는 치료용 조성물 |
| KR20250161566A (ko) | 2023-03-29 | 2025-11-17 | 시젱 하이스코 파마수티칼 씨오., 엘티디. | Cyp11a1 억제제 및 이의 용도 |
| WO2024217531A1 (zh) * | 2023-04-21 | 2024-10-24 | 西藏海思科制药有限公司 | Cyp11a1抑制剂及其用途 |
| AU2024270498A1 (en) * | 2023-05-11 | 2025-11-27 | Foshan Ionova Biotherapeutics Co., Inc. | Novel compounds as cyp11a1 inhibitors and methods of use thereof |
| WO2025017072A1 (en) | 2023-07-19 | 2025-01-23 | Orion Corporation | Stable pharmaceutical compositions of a cyp11a1 inhibitor |
| WO2025021182A1 (en) * | 2023-07-27 | 2025-01-30 | Acerand Therapeutics (Hong Kong) Limited | Cyp11a1 inhibitors |
| WO2025051216A1 (zh) * | 2023-09-08 | 2025-03-13 | 深圳众格生物科技有限公司 | 一种cyp11a1抑制剂、其制备方法及其应用 |
| WO2025168117A1 (zh) * | 2024-02-08 | 2025-08-14 | 盛睿泽华医药科技（苏州）有限公司 | 一种多环化合物及其制备方法和应用 |
| WO2025237211A1 (zh) * | 2024-05-11 | 2025-11-20 | 辽宁海思科制药有限公司 | 一种cyp11a1抑制剂的晶型物及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074450A2 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| WO2004076445A2 (en) * | 2003-02-28 | 2004-09-10 | Exonhit Therapeutics Sa | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014202827A1 (en) * | 2013-06-11 | 2014-12-24 | Orion Corporation | Novel cyp17 inhibitors/antiandrogens |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6176485A (ja) * | 1984-09-20 | 1986-04-18 | Ss Pharmaceut Co Ltd | 新規なγ−ピラン誘導体 |
| AR110412A1 (es) * | 2016-12-22 | 2019-03-27 | Orion Corp | Inhibidores de la cyp11a1 |
-
2017
- 2017-12-20 AR ARP170103609A patent/AR110412A1/es active IP Right Grant
- 2017-12-21 TW TW111114824A patent/TWI796205B/zh active
- 2017-12-21 MA MA47102A patent/MA47102B1/fr unknown
- 2017-12-21 TW TW106145006A patent/TWI762544B/zh active
- 2017-12-21 MA MA055983A patent/MA55983A/fr unknown
- 2017-12-21 PE PE2019001297A patent/PE20191137A1/es unknown
- 2017-12-21 KR KR1020257020993A patent/KR20250097993A/ko active Pending
- 2017-12-21 SI SI201730841T patent/SI3558981T1/sl unknown
- 2017-12-21 EP EP21165964.4A patent/EP3868756A1/en not_active Withdrawn
- 2017-12-21 UA UAA201908272A patent/UA124640C2/uk unknown
- 2017-12-21 DK DK17832250.9T patent/DK3558981T3/da active
- 2017-12-21 US US16/472,377 patent/US10717726B2/en active Active
- 2017-12-21 HR HRP20211255TT patent/HRP20211255T1/hr unknown
- 2017-12-21 PT PT178322509T patent/PT3558981T/pt unknown
- 2017-12-21 TN TNP/2019/000189A patent/TN2019000189A1/en unknown
- 2017-12-21 JP JP2019534192A patent/JP7025432B2/ja active Active
- 2017-12-21 HU HUE17832250A patent/HUE056540T2/hu unknown
- 2017-12-21 ES ES17832250T patent/ES2880151T3/es active Active
- 2017-12-21 EA EA201991513A patent/EA039309B1/ru unknown
- 2017-12-21 PL PL17832250T patent/PL3558981T3/pl unknown
- 2017-12-21 WO PCT/FI2017/050926 patent/WO2018115591A1/en not_active Ceased
- 2017-12-21 KR KR1020237002074A patent/KR102826021B1/ko active Active
- 2017-12-21 NZ NZ755395A patent/NZ755395A/en unknown
- 2017-12-21 MX MX2019007373A patent/MX388538B/es unknown
- 2017-12-21 CA CA3047370A patent/CA3047370A1/en active Pending
- 2017-12-21 KR KR1020197021256A patent/KR102491308B1/ko active Active
- 2017-12-21 CN CN202211597796.4A patent/CN116162084B/zh active Active
- 2017-12-21 CN CN201780079479.4A patent/CN110139861B/zh active Active
- 2017-12-21 RS RS20210994A patent/RS62198B1/sr unknown
- 2017-12-21 AU AU2017380282A patent/AU2017380282B2/en active Active
- 2017-12-21 LT LTEP17832250.9T patent/LT3558981T/lt unknown
- 2017-12-21 EP EP17832250.9A patent/EP3558981B1/en active Active
-
2019
- 2019-06-19 IL IL267484A patent/IL267484B/en unknown
- 2019-06-20 CL CL2019001728A patent/CL2019001728A1/es unknown
- 2019-06-21 PH PH12019550111A patent/PH12019550111A1/en unknown
- 2019-07-09 CO CONC2019/0007321A patent/CO2019007321A2/es unknown
-
2020
- 2020-06-08 US US16/895,221 patent/US11098032B2/en active Active
-
2021
- 2021-05-28 AU AU2021203497A patent/AU2021203497B2/en active Active
- 2021-07-06 US US17/367,849 patent/US12030871B2/en active Active
- 2021-08-19 IL IL285729A patent/IL285729B/en unknown
- 2021-08-25 CY CY20211100760T patent/CY1124461T1/el unknown
-
2022
- 2022-02-10 JP JP2022019891A patent/JP7286825B2/ja active Active
-
2024
- 2024-05-24 US US18/674,603 patent/US20240308989A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003074450A2 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| WO2004076445A2 (en) * | 2003-02-28 | 2004-09-10 | Exonhit Therapeutics Sa | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| US20140005181A1 (en) * | 2012-06-21 | 2014-01-02 | Sanford-Burnham Medical Research Institute | Small molecule antagonists of the apelin receptor for the treatment of disease |
| WO2014202827A1 (en) * | 2013-06-11 | 2014-12-24 | Orion Corporation | Novel cyp17 inhibitors/antiandrogens |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021203497B2 (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors | |
| AU2007315955B2 (en) | Pyridine carboxamides as 11-beta-HSD1 inhibitors | |
| TWI386405B (zh) | 咪唑衍生物 | |
| JP2020530446A (ja) | 化合物、組成物、及び、方法 | |
| CA3178067A1 (en) | Cyp11a1 inhibitors | |
| CA2758210A1 (en) | Proline derivatives as cathepsin inhibitors | |
| CA2742897A1 (en) | Modulators of amyloid beta. | |
| CN101370806A (zh) | 取代的4-苯基哌啶 | |
| US20250154148A1 (en) | Kras inhibitors | |
| HK40016600A (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors | |
| HK40016600B (en) | Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors | |
| BR122024021737A2 (pt) | Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos | |
| BR112019012906B1 (pt) | Compostos derivados de pirano como inibidores de cyp11a1, uso dos mesmos para o tratamento de doenças dependentes de receptor esteroide, particularmente, receptor androgênico e composição e combinação farmacêuticas que compreendem os ditos compostos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PYRAN DERIVATIVES AS CYP11A1 (CYTOCHROME P450 MONOOXYGENASE 11A1) INHIBITORS |
|
| FGA | Letters patent sealed or granted (standard patent) |